Anthony Evnin Ph.D.

Anthony Evnin, Ph.D., lead outside director for Infinity and chair of Infinity’s Nominating and Governance Committee, has been a Partner of Venrock, a venture capital firm, since 1975. Dr. Evnin serves as a director of a number of private companies, as well as AVEO Pharmaceuticals, Inc. a publicly traded biopharmaceutical company. Dr. Evnin is a Trustee of The Rockefeller University, a Trustee of The Jackson Laboratory, a Trustee Emeritus of Princeton University, a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center, a Director of the New York Genome Center, and a Member of the Board of Directors of the Albert and Mary Lasker Foundation. Dr. Evnin received an A.B. in chemistry from Princeton University and a Ph.D. in chemistry from the Massachusetts Institute oAnthony Evnin, Ph.D., lead outside director for Infinity and chair of Infinity’s Nominating and Governance Committee, has been a Partner of Venrock, a venture capital firm, since 1975. Dr. Evnin currently serves on the Board of Directors of AVEO Pharmaceuticals and Juno Therapeutics as well as on the Board of one private company, Constellation Pharmaceuticals. He is a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center, a Trustee of The Rockefeller University, a Trustee of The Jackson Laboratory, a Director of the New York Genome Center, a Member of the Board of Directors of the Albert and Mary Lasker Foundation, and a Trustee Emeritus of Princeton University. Dr. Evnin received an A.B. in chemistry from Princeton University and a Ph.D. in chemistry from the Massachusetts Institute of Technology.f Technology.